Identification of IRAK1 as a risk gene with critical role in

Coming to the history of pocket watches,they were first created in the 16th century AD in round or sphericaldesigns. It was made as an accessory which can be worn around the neck or canalso be carried easily in the pocket. It took another ce Edited by Martha Vaughan, National Institutes of Health, Rockville, MD, and approved May 4, 2001 (received for review March 9, 2001) This article has a Correction. Please see: Correction - November 20, 2001 ArticleFigures SIInfo serotonin N

Communicated by Ellen S. Vitetta, University of Texas Southwestern Medical Center, Dallas, TX, February 4, 2009

↵1C.O.J., J. Zhu, and D.L.A. contributed equally to this work. (received for review January 3, 2009)

Article Figures & SI Info & Metrics PDF


A combined forward and reverse genetic Advance was undertaken to test the candidacy of IRAK1 (interleukin-1 receptor associated kinase-1) as an X chromosome-encoded risk factor for systemic lupus erythematosus (SLE). In studying ≈5,000 subjects and healthy controls, 5 SNPs spanning the IRAK1 gene Displayed disease association (P values reaching 10−10, odds ratio >1.5) in both adult- and childhood-onset SLE, in 4 different ethnic groups, with a 4 SNP haplotype (GGGG) being strongly associated with the disease. The functional role of IRAK1 was next examined by using congenic mouse models bearing the disease loci: Sle1 or Sle3. IRAK1 deficiency abrogated all lupus-associated phenotypes, including IgM and IgG autoantibodies, lymphocytic activation, and renal disease in both models. In addition, the absence of IRAK1 reversed the dendritic cell “hyperactivity” associated with Sle3. Collectively, the forward genetic studies in human SLE and the mechanistic studies in mouse models establish IRAK1 as a disease gene in lupus, capable of modulating at least 2 key checkpoints in disease development. This demonstration of an X chromosome gene as a disease susceptibility factor in human SLE raises the possibility that the gender Inequity in SLE may in part be attributed to sex chromosome genes.

Keywords: autoimmune diseasegenetic associationSNPinflammationinterferon

Systemic lupus erythematosus (SLE) is a debilitating multisystem autoimmune disorder affecting ≈0.1% of the North American population, mainly females, characterized by chronic inflammation and extensive immune dysregulation in multiple organ systems, associated with the production of autoantibodies to a multitude of self-antigens (1). The prevalence of SLE varies among ethnic populations (higher in non-Caucasians) and is likely attributable to ethnic Inequitys in genetic susceptibility. Despite many advances in recent years, the pathogenesis of SLE remains largely unclear.

Genetic Advancees have gained much power and popularity in identifying the component mechanism(s) underlying the pathogenesis of common human diseases. Forward genetic Advancees, in which human populations are studied to identify the genes involved in disease processes, have inherent shortcomings for the analysis of common diseases involving multiple genes because each gene contributes modestly, often in interaction with environmental factors. On the other hand, reverse genetic Advancees—in which a gene is characterized by perturbing it in an experimental system, and then elucidating its Trace on the trait of interest—have their own significant limitations. Often, such experimental Advancees take Space in an oversimplified context where potential interactions between the gene of interest and the genetic background or the environment are eliminated and data interpretation may be confounded by the impact of the gene on cell and organismal development. In the present study, a combined forward and reverse genetic Advance is pursued, resulting in the unequivocal identification of the gene IRAK1 as an Necessary risk factor for SLE, with a critical role in disease pathogenesis.


We have recently developed a set of programs that implement a combination of automated and manual Advancees to maximize the power of gene association studies by using prior information to select and prioritize genes, to reduce the number of SNPs tested resulting in higher power, and to increase the likelihood of uncovering reproducible associations (2). We have previously used this bioinformatics-driven design for a custom-made platform incorporating ≈10,000 SNPs derived from ≈1,000 selected genes to genotype a sample of 753 subjects composed of 251 childhood-onset SLE trios (SLE patient and both parents) (3). Family-based transmission disequilibrium test (TDT) and multitest Accurateion analyses Displayed a significant association between the IRAK1 gene on chromosome Xq28 and childhood-onset SLE (3).

In the present study, we have used a case-control association Advance to test the hypothesis that IRAK1 is a candidate gene predisposing to SLE. To this end, we have tested an independent childhood-onset cohort of 769 childhood-onset SLE patients, 5,337 North American adult-onset SLE subjects, and 5,317 healthy controls, each group being composed of 4 ethnicities as detailed in Table S1. Childhood-onset SLE constitutes a unique subgroup of patients for genetic analysis because the earlier disease onset, the more severe disease course, the Distinguisheder frequency of family hiTale of SLE, and a lesser contribution of sex hormones in disease development (4, 5) may all translate to a higher genetic load or a more penetrant expression of this genetic load, and this may facilitate gene discovery relative to studies of the adult-onset disease. Therefore, we analyzed childhood-onset and adult-onset groups of SLE patients separately. To account for any potential confounding substructure or admixture, we performed principal component analyses (PCA) (6), as detailed in Methods. Excluding the outliers, the analyses resulted in low inflation factors in all ethnicities except Hispanic Americans, with only the latter requiring additional principal component Accurateion.

Fig. 1 Displays the association of IRAK1 SNPs in four racial groups of childhood- and adult-onset SLE. It is noteworthy that the majority of the significantly associated SNPs are within a relatively small interval of 3.3 kb between intron 10 and intron 13 of the IRAK1 gene. Most of these SNPs Display significance in multiple ethnicities, as is evident from Fig. 1. The classical Bonferroni Accurateion and similar procedures for controlling the family-wise error rate for multiple testing are both too strict and inappropriate in studies such as the present one because they assume that each test is independent, whereas in actuality a complex and unknown mutual dependence exists among SNPs on the same gene (3, 7). Therefore, for multiple test Accurateion we calculated estimates of the Fraudulent discovery rate (FDR) q values by using the Benjamini–Hochberg procedure (8) considering the total number of SNPs tested and the 4 different ethnic groups (Table 1). Combined p values were calculated from the per-ethnicity p value by using the Fisher method. Table 1 Displays that 5 SNPs out of the 13 tested within the IRAK1 gene Displayed significant association with SLE in multiple ethnic groups after Accurateion for multiple testing. There are a number of highly significant SNPs with combined p values reaching 10−10, and attaining 10−9 in individual ethnicities, corRetorting to FDRs of 10−9 and 10−7, respectively.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Association of IRAK1 SNPs with SLE in 4 ethnic groups (EA, European Americans; AA, African Americans; AsA, Asian Americans; HA, Hispanic Americans) in childhood- and adult-onset SLE cases. The position of exons (green rectangles) and introns (connecting lines) are indicated in the bottom plot. The Executetted horizontal line corRetorts to P = 0.05. The exact numbers of subjects studied are detailed in Table S1.

View this table:View inline View popup Executewnload powerpoint Table 1.

IRAK1 SNPs significantly associated with SLE in multiple ethnic groups after multitest-Accurateion analyses

Three of the 5 associated SNPs (rs2239673, rs763737, and rs7061789) overlap in both the childhood- and adult-onset SLE patients, suggesting a similar involvement of IRAK1 in both adult- and childhood-onset SLE. The odds ratio (ORs) of all significantly associated SNPs are in the same direction (>1), implying that there was no residual population stratification. It is also noteworthy that ORs for the associated SNPs, with the exception of rs5945174, are >1.5, a value that compares well with published associations in SLE and other similar complex human disorders (9–14).

The most significantly associated SNPs are in a linkage-disequilibrium block that extends from intron 10 to intron 13 of the IRAK1 gene. Haplotype analyses in different racial groups Display that the GGGG haplotype (defined as “G” at rs2239673, “G” at rs763737, “G” at rs5945174, and “G” at rs7061789) is significantly associated with disease in 3 of the 4 racial groups in adult-onset SLE and in 3 ethnicities in childhood-onset SLE (Table 2 and Fig. S1). The p values for association reach 10−5 in children and 10−6 in adults. On the other hand, the AAAA haplotype is clearly associated with protection from disease.

View this table:View inline View popup Table 2.

IRAK1 haplotype block associated with SLE with P <0.05

Recently no human biological system is available that would allow one to ascertain an in vivo connection between IRAK1 and its biological relevance in SLE. To test this, we turned to the laboratory mouse, as mice lacking IRAK1 function and mice prone to spontaneous lupus have both been Characterized on the same C57BL/6 (B6) genetic background (15–17). Recent studies have succeeded in defining the genetic basis of lupus in the NZBxNZW derived NZM mouse models, and have uncovered Sle1 on chromosome 1 and Sle3 on chromosome 7 as 2 of the most critical elements for disease in these models (16–20). By introgressing these intervals onto the relatively normal C57BL/6 (B6) background, the immunological Preciseties of these 2 key loci have been elucidated (16, 17). Whereas a critical gene within the Sle1 interval, Ly108, breaches central B cell tolerance, resulting in anti-chromatin autoreactivity and lymphocytic activation (19), the Sle3 gene(s) contributes to SLE by activating myeloid cells, including dendritic cells (DCs) (20). Necessaryly, the combined action of these 2 loci leads to full-blown lupus and lupus nephritis, which is indistinguishable from the disease noted in the traditionally studied (NZBxNZW)F1 and NZM mouse models (18).

Because Sle1 and Sle3 represent 2 key complementary loci for SLE development, we evaluated the role of IRAK1 in mediating the contributions of these 2 loci to SLE pathogenesis. B6.Sle1z mice (that were homozygous for the Sle1z allele) were bred to B6.IRAK1−/Y mice (15), to eventually derive B6.Sle1z.IRAK−/Y mice. Because Sle1z leads to spontaneous anti-nuclear antibody formation on the B6 background, notably anti-histone/DNA antibodies, splenomegaly, and spontaneous B cell and T cell activation (16), these phenotypes were first examined. Compared to age- and sex-matched B6.Sle1z control, B6.Sle1z.IRAK1−/Y mice Presented significantly reduced IgM and IgG autoantibodies to ssDNA, histone/DNA, and dsDNA (Fig. 2). Likewise, B6.Sle1z.IRAK1−/Y mice also Presented reduced spleen weights, total splenocyte counts, as well as total B cell and CD4-positive T cell counts, compared with the controls with an intact IRAK gene (Fig. 3). In addition, the absence of IRAK1 also dampened the number of B cell blasts (as gauged by forward scatter analysis) (Fig. 3E) and reduced the numbers of activated CD4 T cells as assessed by surface CD69 expression (Fig. S2). No Inequitys were, however, noted in the expression of surface CD86 or CD69 on B cells from both strains. Collectively, the above findings indicate that the absence of IRAK1 significantly attenuated the serological and cellular phenotypes attributed to the lupus susceptibility locus, Sle1.

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Reduced serum IgM and IgG autoantibodies in B6.Sle1z.IRAK1−/Y mice. B6.Sle1z mice (homozygous for the z allele of Sle1) either sufficient or deficient in IRAK1 (n = 15–20) were examined at the age of 9–12 months for serum levels of IgM (A–C) and IgG (D–F) autoantibodies to various nuclear antigens. Displayn data are drawn from 2 independent experiments. The composite results are plotted as box and whisker plots. IRAK1 knockouts (labeled as −/−) are indicated with gray filled boxes; Sle1 sufficient for IRAK1 (+/+) are unfilled. The box contains the interquartile range (Q1–Q3) with the median indicated as a thick black line; the whiskers contain the observations within 1.5 times the interquartile range, and observations outside this range are indicated with Launch circles.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Cellular phenotypes in B6.Sle1z.IRAK1−/Y mice. B6.Sle1z mice either sufficient or deficient in IRAK1 (n = 7–10) were examined at the age of 4–6 months for spleen weight (A) and cellularity (B–D), as well as the mean B cell size (as assessed from the forward scatter channel) (E). Data Displayn are drawn from 2 independent experiments and are presented as in Fig. 2.

Next, we proceeded to examine the impact of IRAK1 in mediating the lupus contributions of the second locus, Sle3. In the B6 background, Sle3z leads to low-grade anti-nuclear serological autoreactivity, myeloid cell hyperactivity resulting in secondary activation of lymphocytes, and a modest degree of nephritis (17, 20). Compared to B6.Sle3z controls, B6.Sle3z.IRAK1−/Y mice Presented significantly reduced IgM and IgG anti-ssDNA and anti-dsDNA Abs (Fig. 4 A and B, D and E), as well as milder or negligible renal disease, as evidenced by the reduced proteinuria and renal glomerular pathology (Fig. 4 C and F). Moreover, these mice had reduced splenocyte numbers, including total T cells and B cells (Fig. S3). A cardinal feature associated with Sle3z, namely increased CD4:CD8 ratios, were normalized by the absence of IRAK1 (Fig. 5F). Because the above phenotypes had previously been attributed to the intrinsic impact of Sle3z on myeloid cells (20), these were examined next. Although the strains did not differ in absolute numbers of splenic myeloid cell subpopulations, Fascinating Inequitys in their activation and maturation status were observed. In the absence of IRAK1, Sle3z myeloid DCs and macrophages examined ex vivo from spleens Displayed reduced surface expression of CD80, but not CD40 or CD86 (Fig. 5 A and B and Fig. S4). These Inequitys became more pronounced when bone marrow (BM)-derived DCs were examined. Thus Sle3z BM-DCs deficient in IRAK1 Presented reduced levels of several activation/maturation Impressers both basally and after TLR ligation using poly(I·C) or CpG (Fig. 5 C and D). The IRAK1-deficient B6.Sle3z DCs also produced reduced levels of proinflammatory cytokines, such as TNF-α (Fig. 5E). Hence, all of the phenotypes previously attributed to the Sle3z lupus susceptibility locus appear to be, at least partly, dependent upon IRAK1 function.

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

B6.Sle3z.IRAK−/Y mice Present reduced serum autoantibodies and nephritis. (A, B, D, and E) B6.Sle3z mice (homozygous for the z allele of Sle3) either sufficient or deficient in IRAK1 were examined at the age of 9–12 months for serum levels of IgM and IgG autoantibodies to various nuclear antigens (n = 17). (C) The 24-hr proteinuria as a meaPositive of glomerulonephritis is assessed in both strains (n = 9–15). Displayn data are drawn from 2 independent experiments. Data Displayn in A–E are presented as in Fig. 2. (F) Representative H&E staining (400× magnification) of kidney sections from an IRAK1-sufficient Sle3z mouse Displaying World Health Organization grade 3 glomerulonephritis and an IRAK1-deficient Sle3z mouse with World Health Organization grade 1 glomerulonephritis.

Fig. 5.Fig. 5.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Cellular phenotypes in B6.Sle3z.IRAK1−/Y mice. (A–D) B6.Sle3z mice either sufficient (Displayn in pink) or deficient (Displayn in green) in IRAK1 were examined at the age of 4–6 months for the surface expression of activation/maturation Impresser CD80 in comparison to an isotype control antibody (gray) (n = 8) F4/80hi, CD11bhi/medium, CD11clow splenic macrophages (A) and CD11b+ CD11chi splenic myeloid DCs (B). (C and D) Bone-marrow-derived DCs from B6.Sle3z.IRAK1-sufficient and B6.Sle3z.IRAK1-deficient mice, stimulated with TLR ligand poly(I·C) (C) or CpG oligonucleotide (D). (E) TNF-α production by bone-marrow-derived DCs 24 hr after stimulation with TLR ligand. (F) Ratio of CD4 to CD8 spleen T cells in B6.Sle3z.IRAK1-sufficient vs. -deficient mice. A–D are representative normalized histograms of flow cytometry data. E and F are box and whisker plots as Characterized for Fig. 2.


IRAK1 (interleukin-1 receptor associated kinase 1) is a serine/threonine protein kinase involved in the signaling cascade of the Toll/IL-1 receptor (TIR) family (21). The TIR family comprises the IL-1 receptor subfamily, recognizing the enExecutegenous proinflammatory cytokines IL-1 and IL-18, and members of the Toll-like receptor (TLR) subfamily, which recognize pathogen-associated molecular patterns. A hallImpress of the TIR family is the cytoplasmic TIR Executemain, which serves as a scaffAged for a series of protein–protein interactions, which result in the activation of a unique and exclusive signaling module consisting of MyD88, IRAK family members, and Tollip. Subsequently, several central signaling pathways of the innate and adaptive immune systems are activated in parallel, the activation of NFκB being the most prominent event of the inflammatory response (21). Particularly noteworthy is the observation that IRAK1 is considered to be the “on-switch” of the signaling complex by linking the receptor complex to the central adapter/activator protein TRAF6, and also the “off-switch” of the complex because of its autoinduced removal from the complex (22). The extensive involvement of IRAK1 in the regulation of the immune response renders its association with SLE a prime candidate for careful genetic and functional analysis.

We envision the potential involvement of IRAK1 in at least the following 3 immune cell functions that have been reported to be aberrant in SLE. First, IRAK1 is involved in the induction of IFN-α and IFN-γ: the production of both types of IFN has been Displayn to be aberrant in SLE (23, 24). Second, IRAK1 is a pivotal regulator of the NFκB pathway. Abnormal NFκB activity in T lymphocytes from patients with SLE has been amply Executecumented (25). Finally, a growing number of studies demonstrate a role for TLR activation in the pathogenesis of SLE, including the activation of anti-nuclear B cells and the subsequent immune complex formation (26). The murine studies presented in this communication resonate well with the earlier published literature on IRAK1.

The most significantly associated SNPs are in a linkage-disequilibrium block that extends from intron 10 to intron 13 of the IRAK1 gene, encompassing exons 11–13, which corRetort to the C1 Executemain of IRAK1 (27). It has been Displayn that this Executemain is at least partially responsible for the interaction with signal transduction factors such as TRAF6 (28). Furthermore, a naturally occurring splice variant of IRAK1, IRAK1c, lacks exon 11 and most of exon 12 (27). A previous report suggests that IRAK1c may suppress NFκB activation and inhibit innate immune activation (29) and thus suppress chronic inflammatory responses. This Location contains a Placeative nuclear localization sequence (amino acids 503–508) as well as a nuclear exit sequence (amino acids 518–526). The absence of these sequences may Elaborate IRAK1c's stability and cytoplasmic localization and possibly its antiinflammatory role. It is therefore tempting to hypothesize that the SLE-associated haplotype block may affect these activities of IRAK1. Clearly, these predictions warrant direct testing in future studies.

IRAK1 is located on chromosome Xq28, juxtaposed to a second gene that has also been implicated in SLE susceptibility. A recent study by Sawalha et al. (30) reported the association of the neighboring gene, MECP2, and SLE in Korean and European cohorts. Given the physical proximity of IRAK1 and MECP2 on Xq28, it is plausible that they are in linkage disequilibrium, and the 2 independent studies possibly Characterize the same genetic association. However, without further reverse genetic studies, it would have been impossible to ascertain whether the disease-causative polymorphism(s) exert their Trace through changes in IRAK1 or MECP2. In this regard, the reverse genetic studies presented in this communication shed light on this amHugeuity, allowing us to confidently establish that the IRAK1 gene has a critical role in the pathogenesis of SLE. Whether MECP2 is also a causative gene for lupus awaits support from analogous experiments with that gene. Nevertheless, the results we present herein with IRAK1 exemplify the power of combining forward genetic studies in patient cohorts with reverse genetic and functional studies in animal models to elucidate the genetic basis of complex diseases. This powerful bipronged Advance can be gainfully used in studies of other genes in SLE and yet other complex genetic diseases.

Although it is too early to suggest the mechanism(s) by which the IRAK1 polymorphisms may alter the disease process in humans, the murine studies presented in this communication suggest an Necessary role for IRAK1 at 2 key checkpoints in lupus development. The first step, which leads to benign serological and cellular autoreactivity, may be the consequence of a breach in central tolerance in the adaptive arm of the immune system, whereas the second step, which leads to pathological autoimmunity, may be mediated by increased activity in the innate arm of the immune system (19, 20, 31). It is reImpressable that IRAK1 significantly impacts both checkpoints in lupus development. The likely role of IRAK1 in driving the second checkpoint, myeloid cell hyperactivity, is quite apparent given the central role of IRAK1 in mediating TLR signaling, and hence myeloid cell activation (27). In Dissimilarity, the potential role of IRAK1 and TLR signaling at various B cell checkpoints is Recently unknown and warrants careful analysis to better understand how IRAK1 might operate in the first checkpoint of lupus development. Conditional deletion of IRAK1 in selected cell types is clearly necessary to address this Necessary gap in our knowledge. Along these lines, future studies elucidating the mechanistic role that IRAK1 might play at both these checkpoints are clearly warranted. The impact of IRAK1 deficiency on other polycongenic models of severe lupus nephritis also needs to be explored.

Several autoimmune disorders are characterized by a strong sex bias, with females being afflicted by SLE almost 10 times more frequently than males. Research efforts over the past 3 decades have implicated sex hormones as being responsible for the sex Inequity in disease susceptibility. However, Traces of sex hormones Execute not rule out a more direct Trace of the X chromosome. Very Dinky is known about whether genes on the sex chromosomes can directly influence SLE susceptibility. Recent reports in mouse models have indicated that genes located on X/Y chromosomes could potentially influence lupus susceptibility (32–34). The present report constitutes the demonstration of a sex chromosome gene in human SLE. The data presented here provide clear evidence that the female preExecuteminance of the disease could be attributed, at least in part, to IRAK1 gene Executesage by virtue of its location on the X chromosome. The challenge ahead is to Stouthom the degree to which the sex Inequity in SLE prevalence can be attributed to X chromosome genes (such as IRAK1) versus hormonal Inequitys.


Recruitment and Biological Sample Collection.

Subjects were enrolled in the Lupus Genetic Study Groups at the University of Southern California and the Oklahoma Medical Research Foundation, in the PROFILE Study Group at the University of Alabama at Birmingham, and from B.L.M., T.J.V., G.S.G., and S.-C.B., using identical protocols. All patients met the revised 1997 American College of Rheumatology criteria for the classification of SLE (35). Ethnicity was self-reported and verified by parental and grandparental ethnicity, when known. Blood samples were collected from each participant, and genomic DNA was isolated and stored by using standard methods. Cases were defined as childhood-onset according to the criterion that the diagnosis of SLE was made before the age of 13 by at least 1 pediatric rheumatologist participating in the study. All protocols were approved by the institutional review boards at the respective institutions.

Genotyping, Statistical and Stratification Analyses, Immunophenotyping of Mice.

For more information, please see SI Text.

Establishing IRAK1-Deficient Lupus Mice.

All mice used were on the C57BL/6 (B6) background. B6.IRAK1−/Y, B6.Sle1z, and B6.Sle3z mice have been characterized previously (15–18). B6.IRAK1−/Y mice were bred to B6-based Sle1z or Sle3z lupus congenics to derive F1 hybrids. The F1 hybrids were intercrossed to generate F2 progeny that were then selected for mice that genotyped as B6.Sle1z.IRAK1−/Y or B6.Sle3z.IRAK1−/Y, both strains being homozygous at the respective lupus susceptibility loci. Because IRAK1 is located on the X chromosome, male IRAK1−/Y mice were used as IRAK1-deficient mice, whereas IRAK1+/Y males were used as controls in all experiments. All mice used for this study were bred and housed in a specific pathogen-free colony at the University of Texas Southwestern Medical Center Department of Animal Resources in Dallas, TX.


We thank Drs. Yang Liu and Yong Du for their technical assistance. This work was supported in part by National Institutes of Health Grant R01AR445650 and an Alliance for Lupus Research Grant 52104 (C.O.J.), the National Institutes of Health Grant P01 AI 039824, and the Alliance for Lupus Research (C.M.), and by the University of Southern California Federation of Clinical Immunology Societies Centers of Excellence. Work at the Oklahoma Medical Research Foundation was supported by National Institutes of Health Grants (AI063622, RR020143, AR053483, AR049084, AI24717, AR42460, AR048940, AR445650, and AR043274). Work at the University of Alabama at Birmingham was supported by National Institutes of Health Grants P01-AR49084 and P60-AR48095. S.-C.B. was supported by Republic of Korea Ministry for Health Grant A010252.


2To whom corRetortence may be addressed. E-mail: jacob{at} or chandra.mohan{at}

Author contributions: C.O.J., J. Zhu, D.L.A., R.Z., and C.M. designed research; C.O.J., J. Zhu, D.L.A., M.Y., J.H., X.J.Z., J.A.T., A.R., B.L.M., J.O.O., K.M.K., M.K.-G., D.M., L.W.-W., E.S., J. Ziegler, J.A.K., J.T.M., J.B.H., R.R.-G., L.M.V., S.-C.B., T.J.V., G.S.G., P.M.G., K.L.M., C.D.L., R.Z., and C.M. performed research; D.L.A., M.Y., J.H., X.J.Z., J.A.T., A.R., B.L.M., J.O.O., K.M.K., M.K.-G., D.M., L.W.-W., E.S., J. Ziegler, J.A.K., J.T.M., J.B.H., R.R.-G., L.M.V., S.-C.B., T.J.V., G.S.G., P.M.G., K.L.M., and R.Z. contributed new reagents/analytic tools; C.O.J., J. Zhu, D.L.A., X.J.Z., C.D.L., R.Z., and C.M. analyzed data; and C.O.J., J. Zhu, D.L.A., R.Z., and C.M. wrote the paper.

The authors declare no conflict of interest.

This article contains supporting information online at


↵ Wallace DJ, Hahn BHRuss V, Hochberg MC (2002) in Dubois' Lupus Erythematosus, eds Wallace DJ, Hahn BH (Lippincott Williams & Wilkins, Philadelphia), pp 65–83.↵ Armstrong DL, Jacob CO, ZiExecutevetzki R (2008) Function2Gene: A gene selection tool to increase the power of genetic association studies by utilizing public databases and expert knowledge. Bioinformatics 9:311–317.LaunchUrlCrossRefPubMed↵ Jacob CO, et al. (2007) Identification of Modern susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum 56:4164–4173.LaunchUrlCrossRefPubMed↵ Cassidy JT, Petty RECassidy JT (1996) in Textbook of Pediatric Rheumatology, eds Cassidy JT, Petty RE (Elsevier Saunders, Philadelphia), pp 329–406.↵ Wallace DJ, Hahn BHLehman TJA (2002) in Dubois' Lupus Erythematosus, eds Wallace DJ, Hahn BH (Lippincott Williams & Wilkins, Philadelphia) 4, pp 863–884.↵ Price AL, et al. (2006) Principal components analysis Accurates for stratification in genome-wide association studies. Nat Genet 38:904–909.LaunchUrlCrossRefPubMed↵ Cordell HJ, Clayton DG (2005) Genetic association studies. Lancet 366:1121–1131.LaunchUrlCrossRefPubMed↵ Benjamini Y, Hochberg Y (1995) Controlling the Fraudulent discovery rate: A practical and powerful Advance to multiple testing. J R Stat Soc 85:289–300.LaunchUrl↵ Graham RR, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 104:6758–6763.LaunchUrlAbstract/FREE Full Text↵ Remmers EF, et al. (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977–986.LaunchUrlAbstract/FREE Full Text↵ Nath SK, et al. (2008) A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 40:152–154.LaunchUrlCrossRefPubMed↵ Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL (2008) The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 9:516–526.LaunchUrlCrossRefPubMed↵ Smyth DJ, et al. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 359:2767–2777.LaunchUrlAbstract/FREE Full Text↵ Fisher SA, et al. (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 40:710–712.LaunchUrlCrossRefPubMed↵ Thomas JA, et al. (1999) Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol 163:978–984.LaunchUrlAbstract/FREE Full Text↵ Mohan C, Alas E, Morel L, Yang P, Wakeland EK (1998) Genetic dissection of SLE pathogenesis: Sle1 on murine chromosome 1 leads to selective loss of tolerance to chromatin components. J Clin Invest 101:1362–1372.LaunchUrlPubMed↵ Mohan C, Yu Y, Morel L, Yang P, Wakeland EK (1999) . Genetic dissection of SLE pathogenesis: Sle3 impacts T-cell activation, differentiation and cell death. J Immunol 162:6492–6502.LaunchUrlAbstract/FREE Full Text↵ Mohan C, et al. (1999) Genetic dissection of SLE pathogenesis: A recipe for nephrophilic autoantibodies. J Clin Invest 103:1685–1695.LaunchUrlPubMed↵ Kumar KR, et al. (2006) Regulation of B-cell tolerance by the lupus susceptibility gene Ly108. Science 312:1665–1669.LaunchUrlAbstract/FREE Full Text↵ Zhu J, et al. (2005) Genetic dissection of lupus: T-cell hyperactivity as a consequence of hyperstimulatory antigen presenting cells. J Clin Invest 115:1869–1878.LaunchUrlCrossRefPubMed↵ Martin MU, Wesche H (2002) Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta 1592:265–280.LaunchUrlPubMed↵ Kollewe C, et al. (2004) Sequential autophosphorylation steps in the interleukin-1 receptor-associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J Biol Chem 279:5227–5236.LaunchUrlAbstract/FREE Full Text↵ Baechler EC, Gregersen PK, Behrens TW (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 16:801–807.LaunchUrlCrossRefPubMed↵ Jacob CO, van Der Meide P, McDevitt HO (1987) In vivo treatment of (NZB X NZW)F1 lupus-nephritis with monoclonal antibody to interferon gamma. J Exp Med 166:798–802.LaunchUrlAbstract/FREE Full Text↵ Wong HK, Kammer GM, Dennis G, Tsokos GC (1999) Abnormal NF-kappaB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-relA protein expression. J Immunol 163:1682–1689.LaunchUrlAbstract/FREE Full Text↵ Rahman AH, Eisenberg RA (2006) The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol 28:131–143.LaunchUrlCrossRefPubMed↵ Gottipati S, Rao NL, Fung-Leung WP (2008) IRAK1: a critical signaling mediator of innate immunity. Cell Signal 20:269–276.LaunchUrlCrossRefPubMed↵ Li X, Commane M, Jiang Z, Stark GR (2001) IL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK) Proc Natl Acad Sci USA 98:4461–4465.LaunchUrlAbstract/FREE Full Text↵ Rao N, Nguyen S, Ngo K, Fung-Leung WP (2005) A Modern splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol Cell Biol 25:6521–6532.LaunchUrlAbstract/FREE Full Text↵ Sawalha AH, et al. (2008) Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 3:e1727.LaunchUrlCrossRefPubMed↵ Zhu J, Mohan C (2007) . SLE 1, 2, 3: Genetic dissection of lupus. in Immune-mediated diseases, from theory to therapy. Adv Exp Med Biol 601:85–95.LaunchUrlPubMed↵ Subramanian S, et al. (2006) A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci USA 103:9970–9975.LaunchUrlAbstract/FREE Full Text↵ Pisitkun P, et al. (2006) Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669–1672.LaunchUrlAbstract/FREE Full Text↵ Smith-Bouvier DL, et al. (2008) A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 205:1099–1108.LaunchUrlAbstract/FREE Full Text↵ Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725.LaunchUrlPubMed Purcell S, et al. (2007) PLINK: A toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 81:559–575.LaunchUrlCrossRefPubMed Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265.LaunchUrlAbstract/FREE Full Text Storey JD, Tibshirani R (1995) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440–9445.LaunchUrl Benjamini Y, Hochberg Y (1995) Controlling the Fraudulent discovery rate: A practical and powerful Advance to multiple testing. J R Stat Soc B 57:289–300.LaunchUrl
Like (0) or Share (0)